Literature DB >> 26063857

Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain.

Carlos Solano1, Rafael de la Cámara2, Lourdes Vázquez3, Javier López4, Estela Giménez5, David Navarro6.   

Abstract

This study gathered information about current practices of cytomegalovirus (CMV) infection management in allogeneic stem cell transplant recipients at Spanish centers. A wide variety of preemptive antiviral therapy strategies for CMV infection guided by real-time PCR assays was found, yet the incidence of CMV disease was low (<3%).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26063857      PMCID： PMC4508446          DOI： 10.1128/JCM.01057-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations.

Authors:  Graeme A m Fraser; Irwin I Walker
Journal:  Biol Blood Marrow Transplant       Date:  2004-05       Impact factor: 5.742

Review 2.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

3.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

Authors:  P Ljungman; R de la Camara; C Cordonnier; H Einsele; D Engelhard; P Reusser; J Styczynski; K Ward
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

4.  Management of cytomegalovirus infection in haemopoietic stem cell transplantation.

Authors:  Vincent Emery; Mark Zuckerman; Graham Jackson; Celia Aitken; Husam Osman; Anthony Pagliuca; Mike Potter; Karl Peggs; Andrew Clark
Journal:  Br J Haematol       Date:  2013-05-06       Impact factor: 6.998

Review 5.  Definitions of cytomegalovirus infection and disease in transplant recipients.

Authors:  Per Ljungman; Paul Griffiths; Carlos Paya
Journal:  Clin Infect Dis       Date:  2002-03-11       Impact factor: 9.079

6.  Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.

Authors:  Dayana Bravo; María Ángeles Clari; Elisa Costa; Beatriz Muñoz-Cobo; Carlos Solano; María José Remigia; David Navarro
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

7.  An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.

Authors:  Margaret Pollack; Judson Heugel; Hu Xie; Wendy Leisenring; Jan Storek; Jo-Anne Young; Manisha Kukreja; Ronald Gress; Marcie Tomblyn; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

8.  An international multicenter performance analysis of cytomegalovirus load tests.

Authors:  Hans H Hirsch; Irmeli Lautenschlager; Benjamin A Pinsky; Laura Cardeñoso; Shagufta Aslam; Bryan Cobb; Regis A Vilchez; Alexandra Valsamakis
Journal:  Clin Infect Dis       Date:  2012-10-24       Impact factor: 9.079

9.  Viral disease prevention after hematopoietic cell transplantation.

Authors:  J Zaia; L Baden; M J Boeckh; S Chakrabarti; H Einsele; P Ljungman; G B McDonald; H Hirsch
Journal:  Bone Marrow Transplant       Date:  2009-10       Impact factor: 5.483
  9 in total
  5 in total

1.  Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood.

Authors:  C Solano; E Giménez; J L Piñana; V Vinuesa; S Poujois; S Zaragoza; M Calabuig; D Navarro
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

2.  When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

Authors:  C Solano; E Giménez; J L Piñana; J C Hernández-Boluda; P Amat; V Vinuesa; D Navarro
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

3.  Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients.

Authors:  David Navarro; Paula Amat; Rafael de la Cámara; Javier López; Lourdes Vázquez; David Serrano; José Nieto; Monserrat Rovira; José Luis Piñana; Estela Giménez; Carlos Solano
Journal:  Open Forum Infect Dis       Date:  2016-05-18       Impact factor: 3.835

Review 4.  CMV in Hematopoietic Stem Cell Transplantation.

Authors:  Rafael de la Cámara
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-06-20       Impact factor: 2.576

5.  Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy.

Authors:  Umberto Restelli; Davide Croce; Valeria Pacelli; Fabio Ciceri; Corrado Girmenia
Journal:  Infect Drug Resist       Date:  2019-05-08       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.